Ambrosia: Evaluating the Effects of a Food-As-Medicine Platform on Gut Microbiome Composition and Metabolism
1 other identifier
interventional
546
1 country
1
Brief Summary
The objective of this study is to test whether dietary behavior modification impacts diet quality and stool microbiome composition and metabolism using microbial whole genome sequencing, targeted metabolomics, and immune profiling. 400 adults 18-64 years old at high risk for CRC (based on past colonoscopy findings or lifestyle risk factors) will be assigned to one of two cohorts, with approximately 200 participants in each.
- Cohort 1 will serve as the control group without any directed dietary modifications.
- Cohort 2 participants will receive medical nutrition therapy (MNT) via 5 Telenutrition (TN) visits with a registered dietitian (RD), utilizing the Academy of Nutrition and Dietetics' Nutrition Care Process. Stool samples will be obtained for each subject at baseline and end of study. Whole genome sequencing, metabolite analysis, and immune profiling will be performed on the samples. Demographic data, general health information, diet and lifestyle information will be collected from the subjects (all self-reported). When applicable, notes from telenutrition appointments will also be collected. Diet information will be collected using the Picture Your Plate(TM) validated food questionnaire.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Nov 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 13, 2023
CompletedFirst Posted
Study publicly available on registry
October 19, 2023
CompletedStudy Start
First participant enrolled
November 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
March 15, 2025
CompletedJuly 31, 2025
July 1, 2025
1.4 years
October 13, 2023
July 28, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Nutrition Counseling Microbiome Impact
Measure microbiome composition before and after 5 telenutrition visits by whole genome sequencing, and determine change in microbial composition as indicated by gUnifrac distance between the two datapoints.
4 months
Study Arms (2)
No Directed Dietary Intervention
NO INTERVENTIONControl group without any directed dietary modifications
Medical Nutrition Therapy
EXPERIMENTALInterventions
Dietitian-led nutrition coaching via 5 Telenutrition visits, utilizing the Academy of Nutrition and Dietetics' Nutrition Care Process.
Eligibility Criteria
You may qualify if:
- Adults 18 to 64 years old at the time of enrollment at high risk for colorectal cancer, defined as follows:
- EITHER a personal history of colorectal cancer, advanced adenoma, or 3 or more non-advanced adenomas in a single screening
- OR TWO of the following criteria:
- One or more first-degree relatives with a history of colorectal cancer
- Body mass index above 30 (Persephone will calculate given height and weight
- Have smoked an average of 5 or more cigarettes (1/4 pack) per day for a continuous period of 10 years or more.
- Able to provide stool samples at study start and after approximately 5 months
- Willing and able to undergo virtual Medical Nutrition Therapy based on cohort assignment
- Willing to complete online questionnaires concerning diet and lifestyle, in English
- Competency in spoken and written English
- Can provide written informed consent
You may not qualify if:
- Subjects with known HIV, Hepatitis A, Hepatitis B, Hepatitis C
- Known Familial Adenomatous Polyposis or Lynch Syndrome (aka Hereditary Non-Polyposis Colorectal Cancer or HNPCC) diagnosis
- A history of Crohn's Disease, Inflammatory Bowel Disease, or chronic colitis.
- Active cancer in the past 2 years, or currently undergoing any form of cancer therapy.
- Confirmed case of COVID-19 or influenza within one month prior to enrollment
- Oral or systemic antibiotic or probiotic use, or a known GI infection, within 3 months prior to enrollment
- Engaged in a nutritional or dietary intervention in the past 3 months.
- Women who are pregnant or plan to become pregnant in the next 6 months, or currently nursing.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Persephone Biosciences, Inc.
San Diego, California, 92121, United States
Related Links
Study Officials
- PRINCIPAL INVESTIGATOR
Charles Baum, MD
Independent
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 13, 2023
First Posted
October 19, 2023
Study Start
November 1, 2023
Primary Completion
March 15, 2025
Study Completion
March 15, 2025
Last Updated
July 31, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will not share